Edwards Lifesciences: Analyst Conviction Builds Ahead of Q3 Print

EW arrives at its November 4 results with short sellers quietly retreating and the analyst community more constructive than at any point this year.

Short interest has fallen nearly 8% over the past week to 1.5% of the free float, continuing a steady unwind that has trimmed positions by roughly 9% over the past month. With borrow availability near its maximum, there is no pressure in the lending market. Borrowing costs are low at 0.57% annualised, albeit up about 9% on the week, a move too small to read as conviction. The options market offers little drama: the put/call ratio of 1.10 sits almost exactly at its 20-day average, a neutral reading that offers no particular lean into the print. The stock itself closed at $92.01, up 3.3% on the week, a divergence from close peers who fell a median of roughly 3% to 5% over the same period. ISRG dropped 4.5%, GMED fell 4.1%, and RMD shed more than 9%, making EW's relative strength notable.

The analyst debate centres on whether Edwards can rebuild its margin profile while sustaining the volume growth in its two key franchises. The bull case is grounded in product-level momentum: TAVR revenues grew 10.6% year-over-year in Q3 and TMTT surged 48.3%, with the Pascal and Evoque platforms driving adoption. Management has guided full-year TMTT revenue of $740 million to $780 million and total company growth of 8% to 10%. Barclays initiated coverage in early October with an Overweight rating and a $110 price target, and the consensus mean target of roughly $102 implies about 11% upside from current levels. Bear-side concern focuses on the margin miss reported last quarter, where adjusted operating margins contracted to 23.7% against a consensus expectation of 25.9%, driven by elevated SG&A spending. Surgical Structural Heart also underperformed. The central question heading into Tuesday's release is whether cost discipline has improved enough to narrow that gap.

Insider activity over the past 90 days leans net negative, with roughly $4.6 million in net sales across recent Form 4 filings. The largest discrete open-market sale was a $237,907 transaction by the CVP for EMEACLA in late August. The CVP for TAVR executed a series of 10b5-1 plan sales, pre-arranged transactions that carry less signalling weight than discretionary trades. No director-level or CEO buying appears in the window. BlackRock remains the largest institutional holder at just over 10% of shares, having added more than 6 million shares in the period to September 30.

The print is ultimately a test of whether EW's volume strength across TAVR and TMTT can translate into the operating leverage the Street expects, and whether management's confidence in the full-year margin trajectory holds after last quarter's miss.